Breaking News, Collaborations & Alliances

Minaris, Genetix Expand Manufacturing Partnership to Increase Production of LYFGENIA

The collaboration significantly increases manufacturing capacity, enabling Genetix to meet growing commercial demand.

Author Image

By: Charlie Sternberg

Associate Editor

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, have expanded their manufacturing partnership to increase commercial-scale production of LYFGENIA, Genetix’s FDA-approved, one-time gene therapy for individuals 12 years and older with sickle ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters